BAX in Situ Hybridization and Proliferating Cell Nuclear Antigen Immunohistochemical Expressions in Salivary Gland Tumours

2014 ◽  
Vol 26 (1) ◽  
pp. 112-120 ◽  
Author(s):  
Qutaiba A. Hussain ◽  
Lehadh M. Al-Azzawi
Keyword(s):  
Salivary Gland ◽  
In Situ Hybridization ◽  
Proliferating Cell Nuclear Antigen ◽  
Nuclear Antigen ◽  
Salivary Gland Tumours ◽  
Proliferating Cell

The evaluation of salivary gland tumours using proliferating cell nuclear antigen

1997 ◽  
Vol 111 (6) ◽  
pp. 551-555 ◽  
Author(s):  
N. J. Trendell-Smith ◽  
J. Oates ◽  
J. Crocker
Keyword(s):  
Salivary Gland ◽  
Proliferating Cell Nuclear Antigen ◽  
Prognostic Value ◽  
Positive Control ◽  
Negative Control ◽  
Anaplastic Carcinoma ◽  
Nuclear Antigen ◽  
Salivary Gland Tumours ◽  
Normal Salivary Gland ◽  
Proliferating Cell

AbstractIn order to assess its discriminating and prognostic value, we studied the immunoreactivity for proliferating cell nuclear antigen (PCNA) in tissue from 52 human salivary gland tumours using the murine monoclonal antibody PC10.The PCNA percentage count, namely, the average number of positive nuclei counted per 100 randomly selected tumour cells was recorded for each tumour. Anaplastic carcinoma was used as a positive control and histologically ‘normal’ salivary gland and tonsil served as a negative control.A PCNA count of 30 per cent was postulated to predict malignancy within a given salivary gland tumour i.e. a PCNA count of 30 per cent or above would indicate malignant potential. This gave a sensitivity of 96.9 per cent and a specificity of 95.2 per cent and a positive predictive value of determining malignancy of 96.8 per cent.We conclude that PCNA immunoreactivity is useful in discriminating between benign and malignant salivary gland tumours and that it may have prognostic value in this diverse group of neoplasms.

Immunoreactivity of proliferating cell nuclear antigen in salivary gland tumours: An assessment of growth potential

1993 ◽  
Vol 422 (6) ◽  
pp. 481-486 ◽  
Author(s):  
Lianjia Yang ◽  
Kouji Hashimura ◽  
Chunlin Qin ◽  
Prashanta Shrestha ◽  
Sinichiro Sumitomo ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Proliferating Cell Nuclear Antigen ◽  
Growth Potential ◽  
Nuclear Antigen ◽  
Salivary Gland Tumours ◽  
Proliferating Cell

scholarly journals In Situ Analysis of Cellular Proliferation in Canine, Feline and Equine Tumors by Immunohistochemistry: A Comparison of Bromodeoxyuridine, Proliferating Cell Nuclear Antigen, and Interchromatin-Associated Antigen Immunostaining Techniques

1994 ◽  
Vol 6 (4) ◽  
pp. 453-457 ◽  
Author(s):  
Alain Pierre Théon ◽  
Loretta Metzger ◽  
Stephen Griffey
Keyword(s):  
Cell Proliferation ◽  
Proliferating Cell Nuclear Antigen ◽  
Cellular Proliferation ◽  
Nuclear Antigen ◽  
Brdu Incorporation ◽  
Immunohistochemical Detection ◽  
Proliferating Cells ◽  
Proliferating Cell

Cell proliferation in canine, feline, and equine tumors was evaluated using immunohistochemical detection of in vitro 5–bromodeoxyuridine (BrdU) incorporation, proliferating cell nuclear antigen (PCNA), and interchromatin-associated antigen (p105). Ten tumors in each species were analyzed. The tumor proliferative fraction (PF) was defined as the percentage of labeled nuclei for 5,000 tumor nuclei counted. Immunoreactivity was observed with all techniques in all species. A good correlation was observed between the proliferative fractions measured with the BrdU (PFBrdU) and PCNA (PFPCNA) techniques ( rs = 0.523, P = 0.0026). There was no correlation between the PFs measured with the BrdU (PFBrdU) and p105 (PFP105) techniques. Using the median values obtained from the different approaches as cutoff points to define slowly and rapidly proliferating tumors, there was an 80% agreement ( P = 0.009) between PFBrdU and PFPCNA and no agreement between PFBrdU and PFP105 The results of this study indicate that both BrdU and PCNA labeling methods can be used reliably for identifying proliferating cells in animal tumors. In addition, PCNA could be used to replace the BrdU method to assess tumor proliferative fraction because it does not require pretreatment of tissues.

scholarly journals Proliferating cell nuclear antigen(PCNA) as a marker of proliferating cells in salivary gland tumors.

1992 ◽  
Vol 34 (4) ◽  
pp. 454-457 ◽  
Author(s):  
Ikuko Ogawa ◽  
Takashi Takata ◽  
Mutsumi Miyauchi ◽  
Hiroshi Ito ◽  
Naokuni Ijuhin ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Proliferating Cell Nuclear Antigen ◽  
Salivary Gland Tumors ◽  
Nuclear Antigen ◽  
Proliferating Cells ◽  
Proliferating Cell

Determination of cell proliferative activity by immnunohistochemical detection of proliferating cell nuclear antigen in N‐methyl nitrosoureainduced rat mammary tumours

2013 ◽  
Vol 3 (4) ◽  
pp. 188-194
Author(s):  
R. Barathidasan ◽  
R. V. S. Pawaiya ◽  
R. B. Rai ◽  
K. Dhama
Keyword(s):  
Papillary Carcinoma ◽  
Proliferating Cell Nuclear Antigen ◽  
Nuclear Antigen ◽  
Nuclear Staining ◽  
Chemical Carcinogen ◽  
Malignant Tumours ◽  
Mammary Tumours ◽  
Proliferating Cell

Rodent experimental models are considered useful experimental systems to study mammary cancer, which occurs in rodents as a result of hormonal imbalance, much like the breast cancer in women. Rodent cells are easier to transform by chemical carcinogen due to their relatively poorer controls of genetic stability and DNA repair systems. Proliferating cell nuclear antigen (PCNA) is one of the most sensitive biomarkers to measure the cell proliferative activities in the neoplasms, especially when the otherwise undetectable PCNA protein over‐expresses to the immunohistochemically detectable levels. In the present study, mammary tumours were induced in Sprague Dawley rats by intraperitoneal administration of N‐methyl nitrosourea (MNU) chemical carcinogen. Palpable tumours were noticed after 60 days postinjection (dpi) with average latency period of 144 days, and 12 (46.15%) of 26 rats developed mammary tumours. A total of 18 tumours were diagnosed in 12 rats, including 2 cases (10%) of hyperplasia, 1 (5%) benign and 17 malignant tumours (85%). Malignant tumours included in situ ductal papillary carcinoma (11.11%), in situ ductal cribriform carcinoma (38.88%), invasive tubular adenocarcinoma (5.56%), invasive papillary carcinoma (16.67%) and invasive cribriform carcinoma (22.22%) were. PCNA immunohistochemistry revealed moderate to strong nuclear staining in neoplastic cells, with highest mean PCNA index of 55.53±10.13 in invasive cribriform carcinoma. The PCNA indices were significantly different (p<0.01; one way ANOVA) between control mammary gland, hyperplasia, benign and malignant tumours. It was concluded that the measurement of PCNA expressing cells employing immunohistochemistry can help in the determination of the level of malignancy in MNU‐induced rat mammary tumours.

Sign in / Sign up

Export Citation Format

Share Document